Cargando…
Major milestones in translational oncology
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964079/ https://www.ncbi.nlm.nih.gov/pubmed/27469586 http://dx.doi.org/10.1186/s12916-016-0654-y |
_version_ | 1782445041784979456 |
---|---|
author | Dragani, Tommaso A. Castells, Antoni Kulasingam, Vathany Diamandis, Eleftherios P. Earl, Helena Iams, Wade T. Lovly, Christine M. Sedelaar, J. P. Michiel Schalken, Jack A. |
author_facet | Dragani, Tommaso A. Castells, Antoni Kulasingam, Vathany Diamandis, Eleftherios P. Earl, Helena Iams, Wade T. Lovly, Christine M. Sedelaar, J. P. Michiel Schalken, Jack A. |
author_sort | Dragani, Tommaso A. |
collection | PubMed |
description | Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies. |
format | Online Article Text |
id | pubmed-4964079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49640792016-07-29 Major milestones in translational oncology Dragani, Tommaso A. Castells, Antoni Kulasingam, Vathany Diamandis, Eleftherios P. Earl, Helena Iams, Wade T. Lovly, Christine M. Sedelaar, J. P. Michiel Schalken, Jack A. BMC Med Forum Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies. BioMed Central 2016-07-28 /pmc/articles/PMC4964079/ /pubmed/27469586 http://dx.doi.org/10.1186/s12916-016-0654-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Forum Dragani, Tommaso A. Castells, Antoni Kulasingam, Vathany Diamandis, Eleftherios P. Earl, Helena Iams, Wade T. Lovly, Christine M. Sedelaar, J. P. Michiel Schalken, Jack A. Major milestones in translational oncology |
title | Major milestones in translational oncology |
title_full | Major milestones in translational oncology |
title_fullStr | Major milestones in translational oncology |
title_full_unstemmed | Major milestones in translational oncology |
title_short | Major milestones in translational oncology |
title_sort | major milestones in translational oncology |
topic | Forum |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964079/ https://www.ncbi.nlm.nih.gov/pubmed/27469586 http://dx.doi.org/10.1186/s12916-016-0654-y |
work_keys_str_mv | AT draganitommasoa majormilestonesintranslationaloncology AT castellsantoni majormilestonesintranslationaloncology AT kulasingamvathany majormilestonesintranslationaloncology AT diamandiseleftheriosp majormilestonesintranslationaloncology AT earlhelena majormilestonesintranslationaloncology AT iamswadet majormilestonesintranslationaloncology AT lovlychristinem majormilestonesintranslationaloncology AT sedelaarjpmichiel majormilestonesintranslationaloncology AT schalkenjacka majormilestonesintranslationaloncology |